|
|
Effect of Ulinastatin combined with Somatostatin in the treatment of acute pancreatitis |
LAI Run-kang LU Zhun-biao |
Department of Emergency, Guangzhou Zengcheng People′s Hospital, Guangdong Province, Guangzhou 511300, China |
|
|
Abstract Objective To explore the effect of Ulinastatin combined with Somatostatin in the treatment of acute pancreatitis in emergency. Methods Sixty patients with acute pancreatitis admitted to our hospital from January 2017 to January 2019 were enrolled in the study. According to the random number table method, they were divided into drug alone treatment group and combined drug treatment group, 30 cases in each group. The drug alone group was treated with Somatostatin, and the combined group was treated with Somatostatin+Ulinastatin. The therapeutic effects on pancreatitis including the time of blood amylase to return to normal range, the time of urinary amylase to return to normal range,hospital stay, acute and chronic health scores (APACHE Ⅱ), urine amylase monitoring level before and after treatment,blood amylase monitoring level, interleukin-6, tumor necrosis factor-α, and adverse reactions in the two groups were compared. Results The total effectiveness rate of the combined drug group was higher than that of the drug alone group, and the difference was statistically significant (P<0.05). The time when the blood amylase returned to the normal range, the time when the urinary amylase returned to the normal range and the hospital stay in the combined drug group were shorter than those in the drug alone group, the difference were statistical singificant (P<0.05). The APACHEⅡscore, urine amylase monitoring, blood amylase monitoring, interleukin-6 and tumor necrosis factor-α in the combined drug group were lower than those in the drug alone group, the difference were statistical singificant (P<0.05).There was no statistical difference in the overall incidence of adverse reactions between the two groups (P>0.05). Conclusion Application of Somatostatin+Ulinastatin is effective in the treatment of pancreatitis, which can improve blood urea gelatinase, control inflammation, facilitate recovery and shorten treatment time.
|
|
|
|
|
[1] |
张振海,庞颖颖,邱兆磊.乌司他丁联合生长抑素治疗急诊重症急性胰腺炎临床疗效观察[J].泰山医学院学报,2019,40(3):207-210.
|
[2] |
向容,冯晓东.乌司他丁联合生长抑素治疗重症胰腺炎疗效评价及对炎症因子的影响[J].名医,2019,(2):265.
|
[3] |
刘云,于洪波.乌司他丁与生长抑素治疗重症急性胰腺炎临床疗效观察[J].医学信息,2019,32(1):160-161.
|
[4] |
邵炜慧,徐鹏.乌司他丁联合生长抑素治疗急性重症胰腺炎的疗效[J].河南医学高等专科学校学报,2018,30(6):566-567.
|
[5] |
王桂良,邱萍,徐林芳,等.生长抑素联合乌司他丁和/或加贝酯治疗重症急性胰腺炎的临床疗效研究[J].中国全科医学,2018,21(34):4241-4245.
|
[6] |
许镇.乌司他丁联合生长抑素治疗急性重症胰腺炎的疗效观察[J].临床合理用药杂志,2018,11(32):57-58.
|
[7] |
曾火明.生长抑素与乌司他丁联合治疗重症急性胰腺炎患者对其血清炎性因子的影响及预后评价[J].临床检验杂志(电子版),2018,7(4):601-602.
|
[8] |
李博.乌司他丁联合生长抑素治疗急性胰腺炎的疗效分析[J].中国农村卫生,2018,1(20):5.
|
[9] |
肖湘,谭如意,肖铎.乌司他丁联合生长抑素对重症急性胰腺炎患者血清学相关指标的影响[J].医学理论与实践,2018,31(19):2900-2902.
|
[10] |
乔增海,尚志博.乌司他丁对重症脓毒症患者血浆PCT、CRP 水平的影响及对心肝肾的保护作用[J].河北医药,2018,40(8):1172-1174,1179.
|
[11] |
梅洪亮,黄致远,李汉军,等.胰岛素强化联合乌司他汀对中重度急性胰腺炎的近期疗效观察[J].临床外科杂志,2018,26(5):354-356.
|
[12] |
王有广,席向艳,席向利,等.柴黄清胰活血颗粒联合乌司他丁治疗急性胰腺炎临床研究[J].中国药业,2019,28(4):60-62.
|
[13] |
杨东星,兰涛.大柴胡汤联合乌司他丁对肝郁气滞型轻症急性胰腺炎患者血清白细胞介素-1β 和白细胞介素-6的影响[J].现代中西医结合杂志,2018,27(7):689-691,791.
|
[14] |
杨凯凯,杨惠珍.乌司他丁治疗急性胰腺炎的疗效及对血清炎性因子的影响[J].内蒙古医学杂志,2018,50(9):1056-1057.
|
[15] |
肖嘉新,王大海,江芸,等.生长抑素联合乌司他丁对急性胰腺炎患者血清脂肪酶TNF-α 及CRP 水平的影响[J].基层医学论坛,2019,23(7):934-935.
|
|
|
|